Literature DB >> 10744073

Ethylnitrosourea induces neoplasia in zebrafish (Danio rerio).

L G Beckwith1, J L Moore, G S Tsao-Wu, J C Harshbarger, K C Cheng.   

Abstract

The zebrafish (Danio rerio) has been successfully used to discover hundreds of genes involved in development and organogenesis. To address the potential of zebrafish as a cancer model, it is important to determine the susceptibility of zebrafish to tumors. Germ line mutations are most commonly induced for zebrafish mutant screens by exposing adult male zebrafish to the alkylating agent, ethylnitrosourea (ENU). To determine whether ENU induces tumors, we compared the incidence of tumors in ENU-treated fish with untreated controls. Interestingly, 18 of 18 (100%) fish mutagenized with either 2.5 or 3.0 mM ENU developed epidermal papillomas, which numbered 1 to 22 per fish, within 1 year of treatment. The induced epidermal lesions included epidermal hyperplasia, flat papillomas (0.2 to 1.2 mm), and pedunculated papillomas (1.2 to 8 mm in greatest dimension), but no skin cancers. Angiogenesis was evident in papillomas larger than approximately 1 mm. All but two papillomas contained the three cell types (keratinocytes, club, and mucous cells) of normal zebrafish epidermis; histologic variants lacked either club cells or mucous cells. Two cavernous hemangiomas and a single malignant peripheral nerve sheath tumor were also found in the treated fish. None of five untreated controls developed tumors. These studies establish the feasibility of the zebrafish as an experimental model for the study of skin tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744073     DOI: 10.1038/labinvest.3780042

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  27 in total

Review 1.  Fishing for novel angiogenic therapies.

Authors:  Kameha R Kidd; Brant M Weinstein
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

2.  Transgenic expression of walleye dermal sarcoma virus rv-cyclin (orfA) in zebrafish does not result in tissue proliferation.

Authors:  Thomas A Paul; Joel Rovnak; Sandra L Quackenbush; Kathleen Whitlock; Huiqing Zhan; Zhiyuan Gong; Jan Spitsbergen; Paul R Bowser; James W Casey
Journal:  Mar Biotechnol (NY)       Date:  2010-03-28       Impact factor: 3.619

Review 3.  Whole-Organism Cellular Pathology: A Systems Approach to Phenomics.

Authors:  K C Cheng; S R Katz; A Y Lin; X Xin; Y Ding
Journal:  Adv Genet       Date:  2016-07-29       Impact factor: 1.944

Review 4.  High-throughput screening and small animal models, where are we?

Authors:  Jean Giacomotto; Laurent Ségalat
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 5.  Cross-species oncogenomics using zebrafish models of cancer.

Authors:  Richard M White
Journal:  Curr Opin Genet Dev       Date:  2015-06-09       Impact factor: 5.578

Review 6.  Viral diseases in zebrafish: what is known and unknown.

Authors:  Marcus J Crim; Lela K Riley
Journal:  ILAR J       Date:  2012

7.  Neoplasia and neoplasm-associated lesions in laboratory colonies of zebrafish emphasizing key influences of diet and aquaculture system design.

Authors:  Jan M Spitsbergen; Donald R Buhler; Tracy S Peterson
Journal:  ILAR J       Date:  2012

8.  Transgenic expression of walleye dermal sarcoma virus rv-cyclin gene in zebrafish and its suppressive effect on liver tumor development after carcinogen treatment.

Authors:  Huiqing Zhan; Jan M Spitsbergen; Wei Qing; Yi Lian Wu; Thomas A Paul; James W Casey; Guor Muor Her; Zhiyuan Gong
Journal:  Mar Biotechnol (NY)       Date:  2010-01-06       Impact factor: 3.619

9.  Skin color in fish and humans: impacts on science and society.

Authors:  Keith C Cheng
Journal:  Zebrafish       Date:  2008-12       Impact factor: 1.985

10.  Comparative analysis of fixation and embedding techniques for optimized histological preparation of zebrafish.

Authors:  Jean E Copper; Lynn R Budgeon; Christina A Foutz; Damian B van Rossum; Daniel J Vanselow; Margaret J Hubley; Darin P Clark; David T Mandrell; Keith C Cheng
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2017-11-20       Impact factor: 3.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.